The in vivo mouse experiments, along with clinical data analysis (Supplementary Figs. 2A, 3A, and Fig. 2A), unequivocally demonstrate a substantial rise in MAS-mediated ERK pathway activation and its pro-proliferative effects in the absence of MAGI3, even in the early stages of ccRCC (Fig. 6H). Here, MAS1 is linked to nonpapillary renal cell carcinoma.